**Question:** Antiemetic of choice in chemotherapy-induced vomiting

**Core Concept:** Chemotherapy-induced vomiting is a common side effect of cancer treatment. Antiemetics are medications used to prevent and manage these symptoms. Selective 5-HT3 receptor antagonists are a class of antiemetics that effectively reduce nausea and vomiting caused by chemotherapy.

**Why the Correct Answer is Right:**
In the context of chemotherapy-induced vomiting, the correct answer, **D.** Ondansetron, is a selective 5-HT3 receptor antagonist. This class of antiemetics works by blocking serotonin receptors in the chemoreceptor trigger zone (CTZ) in the brainstem, preventing the sensation of nausea and vomiting. Ondansetron's efficacy lies in its selective binding to 5-HT3 receptors, which are primarily involved in the emetic response to chemotherapy.

**Why Each Wrong Option is Incorrect:**
A. **Option A (Rolapitant):** Rolapitant is a neurokinin-1 (NK1) receptor antagonist, not a 5-HT3 receptor antagonist. NK1 receptor antagonists are effective against delayed emesis but not immediate emesis induced by chemotherapy.

B. **Option B (Palonosetron):** Palonosetron is another 5-HT3 receptor antagonist, similar to Ondansetron. However, it has a longer half-life and higher receptor affinity, which may contribute to its superior efficacy or safety profile in certain patient populations, but it is not the primary reason for choosing it over Ondansetron in this context.

C. **Option C (Fosaprepitant):** Fosaprepitant is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, not a 5-HT3 receptor antagonist. Aprepitant is effective against delayed emesis but not immediate emesis induced by chemotherapy.

**Clinical Pearl:** In selecting antiemetics for chemotherapy-induced vomiting, consider the type and duration of emesis (immediate vs. delayed), as well as patient factors like age, pregnancy, and renal function. A combination of an NK1 receptor antagonist (aprepitant) and a 5-HT3 receptor antagonist (Ondansetron) provides better prevention of both acute and delayed emesis in most adult patients undergoing highly emetogenic chemotherapy regimens.

**Correct Answer Explanation:**
Ondansetron is a selective 5-HT3 receptor antagonist, making it the correct choice for managing immediate emesis induced by chemotherapy. It targets the chemoreceptor trigger zone (CTZ) in the medulla oblongata, blocking the stimulation of emetic pathways and preventing nausea and vomiting. Its use is supported by multiple clinical trials and guidelines, including the American Society of Clinical Oncology (ASCO) guidelines for antiemetic therapy in cancer chemotherapy.